The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
An expedient synthesis of oxazepino and oxazocino quinazolines
作者:Albertus Wijnand Hensbergen、Vanessa R. Mills、Ian Collins、Alan M. Jones
DOI:10.1016/j.tetlet.2015.10.008
日期:2015.11
A synthetic route to a new class of privileged tri- and tetra-cyclic quinazolines containing a medium-sized ring is reported. An expedient synthetic route involving nucleophilic aromatic substitution, and sequential Niementowski and BOP-mediated ring closures afforded a collection of analogues. The scope of the reaction was explored in terms of cyclic and acyclic linkers, ring size and substitution pattern. (C) 2015 Elsevier Ltd. All rights reserved.
The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.